15 completed, 2 recruiting, 1 terminated, 1 unknown. 20 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 15, Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Functional Dyspepsia: new trials by email Literature Review of Functional Dyspepsia trials Research Report on Functional Dyspepsia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy - Functional Dyspepsia | Phase 2 / Phase 3 | Recruiting | Md. Moktadirul Hoque Shuvo | 120 | 2025-07-01 | 2026-05-07 |
| Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets - Functional Dyspepsia | Phase 3 | Completed | Abbott | 564 | 2024-02-28 | 2026-04-03 |
| Clinical Trial of DA-5212 in Patients with Functional Dyspepsia DA-5212, DA-5212-R - Functional Dyspepsia | Phase 3 | Completed | Dong-A ST Co., Ltd. | 384 | 2023-06-06 | 2024-12-13 |
| DLBS2411 Treatment For Functional Dyspepsia Placebo caplet of DLBS2411, DLBS2411 - Functional Dyspepsia | Phase 3 | Completed | Dexa Medica Group | 106 | 2022-12-09 | 2026-02-17 |
| A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia Acotiamide hydrochloride hydrate, Placebo - Functional Dyspepsia | Phase 3 | Completed | Zeria Pharmaceutical | 55 | 2021-02-22 | 2026-07-24 |
| Nortriptyline for the Treatment of Functional Dyspepsia Nortriptyline, Placebo - Functional Dyspepsia | Phase 3 | Terminated | Maastricht University Medical Center | 96 | 2018-09-01 | 2025-07-03 |
| Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) DWJ1252, Gasmotin, Placebo of Gasmotin - Functional Dyspepsia | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 124 | 2017-04-24 | 2019-06-26 |
| The Efficacy and Safety of "BST104" (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects BST-104 (Lonicera Flos Extract), Placebo oral tablet - Functional Dyspepsia, Irritable Bowel Syndrome | Phase 3 | Completed | Seoul National University Bundang Hospital | 92 | 2017-02-13 | 2023-04-18 |
| Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia DWJ1252, Gasmotin - Functional Dyspepsia | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 124 | 2016-12-12 | 2019-06-26 |
| Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients. Motireb 5/100 mg, Mosapride citrate, Placebo - Functional Dyspepsia | Phase 3 | Unknown | IlDong Pharmaceutical Co Ltd | 354 | 2016-04-01 | 2016-07-13 |
| Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia Imonogas, Espumisan - Functional Dyspepsia | Phase 3 | Completed | Johnson & Johnson Consumer and Personal Products Worldwide | 210 | 2016-02-01 | 2016-12-15 |
| Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Ketotifen, Placebo - Functional Dyspepsia | Phase 3 | Recruiting | Craig A. Friesen, MD | 40 | 2015-08-01 | 2026-01-09 |
| Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia UI05MSP015CT, Gasmotin - Functional Dyspepsia | Phase 3 | Completed | Korea United Pharm. Inc. | 143 | 2014-11-05 | 2017-07-21 |
| Rifaximin for Functional Dyspepsia Rifaximin, Placebo - Functional Dyspepsia | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 95 | 2013-01-01 | 2015-12-02 |
| Acupuncture for Patients With Function Dyspepsia acupuncture, sham acupuncture - Functional Dyspepsia, Postprandial Distress Syndrome | Phase 2 / Phase 3 | Completed | Chengdu University of Traditional Chinese Medicine | 200 | 2012-09-01 | 2014-12-02 |
| Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition Gabapentin, Placebo - Functional Dyspepsia | Phase 3 | Withdrawn | 59th Medical Wing | 2010-03-01 | 2020-10-01 | |
| To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Z-338, Placebo - Functional Dyspepsia | Phase 3 | Completed | Zeria Pharmaceutical | 820 | 2008-09-01 | 2010-11-23 |
| A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia YM443 - Dyspepsia, Functional Dyspepsia | Phase 3 | Completed | Astellas Pharma Inc | 412 | 2008-08-01 | 2014-10-29 |
| Helicobacter Eradication Relief of Dyspeptic Symptoms Amoxicillin, Clarythromycin, Omeprazole for ten days - Functional Dyspepsia | Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 407 | 2006-10-01 | 2018-03-01 |
| Itopride in Functional Dyspepsia:a Dose Finding Study Itopride (drug) - Functional Dyspepsia | Phase 2 / Phase 3 | Completed | Royal Adelaide Hospital | 500 | 2000-12-01 | 2006-05-04 |
Dyspepsia (3) · Abdominal Pain (1) · Anorexia (1) · Eosinophilia (1) · Gastritis (1) · Heartburn (1) · Irritable Bowel Syndrome (1) · Nausea (1) · Signs and Symptoms, Digestive (1) · Vomiting (1)
Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Signs and Symptoms, Digestive (3) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Gastroenteritis (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Intestinal Diseases (1) · Leukocyte Disorders (1) · Neurologic Manifestations (1) · Pain (1) · Stomach Diseases (1)
Z 338 (2) · mosapride (2) · Acupuncture Therapy (1) · Amoxicillin (1) · Espumisan (1) · Gabapentin (1) · Ketotifen (1) · Nortriptyline (1) · Omeprazole (1) · Pharmaceutical Preparations (1) · Rifaximin (1) · itopride (1)
Daewoong Pharmaceutical Co. LTD. (2) · Zeria Pharmaceutical (2) · 59th Medical Wing (1) · Abbott (1) · Astellas Pharma Inc (1) · Chengdu University of Traditional Chinese Medicine (1) · Craig A. Friesen, MD (1) · Dexa Medica Group (1) · Dong-A ST Co., Ltd. (1) · Hospital de Clinicas de Porto Alegre (1) · IlDong Pharmaceutical Co Ltd (1) · Johnson & Johnson Consumer and Personal Products Worldwide (1) · Korea United Pharm. Inc. (1) · Maastricht University Medical Center (1) · Md. Moktadirul Hoque Shuvo (1)
South Korea (5) · Japan (3) · China (2) · United States (2) · Armenia (1) · Bangladesh (1) · Brazil (1) · Germany (1) · Indonesia (1) · Malaysia (1) · Netherlands (1) · Philippines (1) · Russia (1) · Thailand (1) · Vietnam (1)
Agasjtya W Wardhana, MD, Sp.PD-KGEH (1) · Ari F Syam, Prof, MD, Sp.PD-KGEH (1) · Carlos F Francesconi, MD, PhD (1) · Coana Sukmagautama, MD, Sp.PD, M.Kes. (1) · Craig A Friesen, MD (1) · Elisabeth Kruse (1) · Fan-rong Liang, MD (1) · Gerald J Holtmann, MD (1) · Guilherme B Sander, MD, MsC (1) · Hery D Purnomo, Dr, MD, Sp.PD-KGEH (1) · Jeffrey W Molloy, MD (1) · Luiz E Mazzoleni, MD, MsC, PhD (1) · Michio Hongo, Professor (1)
PMID 16495395, PMID 21839884, PMID 22123802, PMID 22157329, PMID 23901030, PMID 28112426, PMID 31945816, PMID 38771467, PMID 41616902, PMID 42530136
2017 (1)